ClinicalTrials.gg
TerminatedNCT03694197Updated Jun 15, 2021Results posted

Long Term Safety Study of PRALUENT

A Phase 4 interventional study of Praluent in Heterozygous Familial Hypercholesterolemia and Non-familial Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Terminated at 124 sites in 6 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-06-15.

Sponsored by Regeneron Pharmaceuticals · Phase 4, Interventional, and Treatment

Why this study was terminated
The primary objective (to evaluate the long-term safety of Praluent) was adequately evaluated in other studies.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,389
Allocation
Not applicable
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
3rd of 43
1,389 · median 107
Started
2018
with 3 others
Phase 4
5 of 43
1 open now
Registered
40th of 43
by date
Lead sponsor
11 of 43
Regeneron Pharmaceuticals

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 3rd largest by enrollment, is one of 4 that started in 2018, is one of 5 in phase 4, and was the 40th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

The primary objective of the study was to evaluate the long term safety of PRALUENT in participants with heterozygous familial hypercholesterolemia (heFH) or non-familial hypercholesterolemia (FH) participants at high or very high cardiovascular risk who completed the neurocognitive function study R727-CL-1532 (NCT02957682).

The secondary objectives of the study were:

  • To evaluate the effect of PRALUENT on low-density lipoprotein cholesterol (LDL-C)
  • To evaluate the effect of PRALUENT on other lipid parameters
  • To evaluate the effect of PRALUENT on gonadal steroid hormones
03

Conditions studied

  • Heterozygous Familial Hypercholesterolemia
  • Non-familial Hypercholesterolemia
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Participants randomized into the neurocognitive function study (R727-CL-1532) who completed treatment and the end of study (EOS) visit with no premature or permanent discontinuation of study drug.

Key Exclusion Criteria:

  1. Significant protocol deviation in the parent study (neurocognitive function study R727-CL-1532: NCT02957682) based on the investigator's or sponsor's judgment, such as noncompliance
  2. Any participant who experienced an AE leading to permanent discontinuation from the neurocognitive function study R727-CL-1532 (NCT02957682).
  3. Any new condition or worsening of an existing condition which, in the opinion of the investigator or per the PRALUENT local label, would make the participant unsuitable for enrollment or could interfere with the participant participating in or completing the open-label extension (OLE) study
  4. Known to monoclonal antibody or any component of the drug product
  5. Pregnant or breastfeeding women

Note: Other inclusion/ exclusion criteria apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,389 participants (actual)

Study arms

  • Experimental
    Open label

    Drug: Praluent

Interventions

  • Subcutaneous (SC) administration

    Also known as: Alirocumab, REGN727, SAR236553

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AE) After First Administration of Study Drug Through the Last Dose of Study Drug Plus 2 Weeks

    An AE is any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. AEs include serious adverse events (SAEs), AEs leading to treatment discontinuation, and adverse events of special interest (AESI). AESI include local injection site reactions, general allergic events, elevated alanine aminotransferase (ALT) levels greater than or equal to (≥) 3 upper limit normal (ULN) (if baseline is less than (\<) ULN)/ALT ≥2 x ULN (if baseline ≥ ULN), neurologic events, neurocognitive events (according to Customized Medical Dictionary for Regulatory Activities \[MedDRA\] Query \[CMQ\] by Sponsor grouping and CMQ by FDA grouping), cataract, new onset diabetes (NOD), hepatic disorders, and diabetes mellitus (DM)/diabetic complications.

    Time frame: After first administration of study drug through the last dose of study drug plus 2 weeks, up to 80 weeks

Secondary outcomes

  1. Calculated Low-density Lipoprotein Cholesterol (LDL-C) Values From Baseline Over Time

    The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

    Time frame: Up to week 72

  2. Percent Change in LDL-C From Baseline Over Time

    Time frame: Up to week 72

  3. Total Cholesterol (Total-C) Values From Baseline Over Time

    The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

    Time frame: Up to week 72

  4. Percent Change From Baseline in Total-C Over Time

    Time frame: Up to week 72

  5. Lipoprotein a (Lp(a)) Values From Baseline Over Time

    The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

    Time frame: Up to week 72

  6. Percent Change From Baseline in Lp(a) Over Time

    Time frame: Up to week 72

  7. Non-high-density Lipoprotein Cholesterol (Non-HDL-C) Values From Baseline Over Time

    The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

    Time frame: Up to week 72

  8. Percent Change From Baseline in Non-HDL-C Over Time

    Time frame: Up to week 72

  9. High-density Lipoprotein Cholesterol (HDL-C) Values From Baseline Over Time

    The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

    Time frame: Up to week 72

  10. Percent Change From Baseline in HDL-C Over Time

    Time frame: Up to week 72

  11. Fasting Triglycerides (TGs) Values From Baseline Over Time

    The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

    Time frame: Up to week 72

  12. Percent Change From Baseline in Fasting TGs Over Time

    Time frame: Up to week 72

  13. Apolipoprotein B (Apo B) Values From Baseline Over Time

    The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

    Time frame: Up to week 72

  14. Percent Change From Baseline in Apo B Over Time

    Time frame: Up to week 72

  15. Apolipoprotein-A1 (Apo A1) Values From Baseline Over Time

    The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

    Time frame: Up to week 72

  16. Percent Change From Baseline in Apo A1 Over Time

    Time frame: Up to week 72

  17. Gonadal Hormone (Follicle Stimulating Hormone [FSH] and Luteinizing Hormone [LH]) Values for Female Participants From Baseline Over Time

    The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

    Time frame: Up to week 72

  18. Change From Baseline in Gonadal Hormones (FSH and LH) for Female Participants Over Time

    Time frame: Up to week 72

  19. Gonadal (FSH and LH) Hormone Values for Male Participants From Baseline Over Time

    The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

    Time frame: Up to week 72

  20. Change From Baseline in Gonadal Hormones (FSH and LH) for Male Participants Over Time

    Time frame: Up to week 72

  21. Gonadotropin (Estradiol) Values for Female Participants From Baseline Over Time

    The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

    Time frame: Up to week 72

  22. Change From Baseline in Gonadotropins (Estradiol) for Female Participants Over Time

    Time frame: Up to week 72

  23. Gonadotropin (Testosterone) Values for Male Participants From Baseline Over Time

    The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

    Time frame: Up to week 72

  24. Change From Baseline in Gonadotropins (Testosterone) for Male Participants Over Time

    Time frame: Up to week 72

  25. Alanine Aminotransferase Values From Baseline Over Time

    The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

    Time frame: Up to week 72

  26. Change From Baseline in Alanine Aminotransferase Over Time

    Time frame: Up to week 72

  27. Aspartate Aminotransferase Values From Baseline Over Time

    The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

    Time frame: Up to week 72

  28. Change From Baseline in Aspartate Aminotransferase Over Time

    Time frame: Up to week 72

  29. Alkaline Phosphatase Values From Baseline Over Time

    The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

    Time frame: Up to week 72

  30. Change From Baseline in Alkaline Phosphatase Over Time

    Time frame: Up to week 72

  31. Total Bilirubin Values From Baseline Over Time

    The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

    Time frame: Up to week 72

  32. Change From Baseline in Total Bilirubin Over Time

    Time frame: Up to week 72

07

Results

Posted Jun 15, 2021

Participant flow

The 1389 participants who completed double-blind treatment and the end-of-study (EOS) visit in R727-CL-1532 (NCT02957682) signed consent and were screened for this open-label study (EOS visit corresponded to day 1/visit 1 of this study).

Participant flow — Overall Study
MilestoneAlirocumab 75 Q2W/Up150 Q2W
Started1385
Completed0
Not completed1385
Withdrew: Adverse event9
Withdrew: Protocol became inconvenient to participate1
Withdrew: Physician decision4
Withdrew: Study terminated by sponsor1350
Withdrew: Participant moved5
Withdrew: Participant withdrew consent10
Withdrew: Related to imp administration1
Withdrew: Not disclosed5

Outcome measures

PrimaryNumber of Participants With Adverse Events (AE) After First Administration of Study Drug Through the Last Dose of Study Drug Plus 2 Weeks

An AE is any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. AEs include serious adverse events (SAEs), AEs leading to treatment discontinuation, and adverse events of special interest (AESI). AESI include local injection site reactions, general allergic events, elevated alanine aminotransferase (ALT) levels greater than or equal to (≥) 3 upper limit normal (ULN) (if baseline is less than (\<) ULN)/ALT ≥2 x ULN (if baseline ≥ ULN), neurologic events, neurocognitive events (according to Customized Medical Dictionary for Regulatory Activities \[MedDRA\] Query \[CMQ\] by Sponsor grouping and CMQ by FDA grouping), cataract, new onset diabetes (NOD), hepatic disorders, and diabetes mellitus (DM)/diabetic complications.

Time frame:
After first administration of study drug through the last dose of study drug plus 2 weeks, up to 80 weeks
Reported as:
Number · Participants
Number of Participants With Adverse Events (AE) After First Administration of Study Drug Through the Last Dose of Study Drug Plus 2 Weeks
ParticipantsAlirocumab 75 Q2W/Up150 Q2W
Any treatment emergent adverse event (TEAE)568
Any treatment emergent serious adverse event (SAE)89
Any TEAE leading to death5
Any TEAE leading to permanent treatment discontinuation9
Any neurocognitive disorders TEAE (by Sponsor CMQ)4
Any neurocognitive disorders TEAE (by FDA CMQ)0
Any NOD; # analyzed = # of participants w/out diabetes at baseline15
Any hepatic disorders TEAE14
Any neurological TEAE15
Any general allergic TEAE25
At least one treatment-emergent injection site reaction22
Any cataract TEAE5
Any elevated ALT ≥3 ULN1
Any DM/diabetic complications TEAE; # analyzed = # of participants w/diabetes at baseline41
Any DM/diabetic complications TEAE; # analyzed = # of participants w/out diabetes at baseline3
SecondaryCalculated Low-density Lipoprotein Cholesterol (LDL-C) Values From Baseline Over Time

The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

Time frame:
Up to week 72
Reported as:
Mean · Milligrams per decilitre (mg/dL)
Calculated Low-density Lipoprotein Cholesterol (LDL-C) Values From Baseline Over Time
Milligrams per decilitre (mg/dL)Alirocumab 75 Q2W/Up150 Q2W
Baseline117.8 ± 40.67
Week 858.9 ± 37.31
Week 1263.6 ± 40.79
Week 2456.2 ± 36.59
Week 4856.8 ± 36.13
Week 7252.2 ± 38.80
SecondaryPercent Change in LDL-C From Baseline Over Time
Time frame:
Up to week 72
Reported as:
Mean · Percent Change
Percent Change in LDL-C From Baseline Over Time
Percent ChangeAlirocumab 75 Q2W/Up150 Q2W
Week 8-48.74 ± 31.121
Week 12-44.64 ± 35.338
Week 24-50.75 ± 30.249
Week 48-52.35 ± 27.929
Week 72-51.21 ± 32.742
SecondaryTotal Cholesterol (Total-C) Values From Baseline Over Time

The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

Time frame:
Up to week 72
Reported as:
Mean · mg/dL
Total Cholesterol (Total-C) Values From Baseline Over Time
mg/dLAlirocumab 75 Q2W/Up150 Q2W
Baseline199.5 ± 48.88
Week 8139.5 ± 44.76
Week 12145.0 ± 48.68
Week 24137.3 ± 44.18
Week 48139.5 ± 44.53
Week 72131.7 ± 43.25
SecondaryPercent Change From Baseline in Total-C Over Time
Time frame:
Up to week 72
Reported as:
Mean · Percent Change
Percent Change From Baseline in Total-C Over Time
Percent ChangeAlirocumab 75 Q2W/Up150 Q2W
Week 8-28.68 ± 20.158
Week 12-25.99 ± 23.058
Week 24-29.98 ± 20.930
Week 48-30.89 ± 21.004
Week 72-31.55 ± 22.238
SecondaryLipoprotein a (Lp(a)) Values From Baseline Over Time

The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

Time frame:
Up to week 72
Reported as:
Mean · mg/dL
Lipoprotein a (Lp(a)) Values From Baseline Over Time
mg/dLAlirocumab 75 Q2W/Up150 Q2W
Baseline39.7 ± 47.86
Week 835.0 ± 41.99
Week 1232.7 ± 39.42
Week 2433.9 ± 42.54
Week 4838.6 ± 50.66
Week 7240.4 ± 56.47
SecondaryPercent Change From Baseline in Lp(a) Over Time
Time frame:
Up to week 72
Reported as:
Mean · Percent Change
Percent Change From Baseline in Lp(a) Over Time
Percent ChangeAlirocumab 75 Q2W/Up150 Q2W
Week 8-12.69 ± 35.452
Week 1210.63 ± 228.659
Week 24-6.80 ± 110.827
Week 48-7.89 ± 116.831
Week 72-22.23 ± 28.233
SecondaryNon-high-density Lipoprotein Cholesterol (Non-HDL-C) Values From Baseline Over Time

The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

Time frame:
Up to week 72
Reported as:
Mean · mg/dL
Non-high-density Lipoprotein Cholesterol (Non-HDL-C) Values From Baseline Over Time
mg/dLAlirocumab 75 Q2W/Up150 Q2W
Baseline152.4 ± 48.81
Week 888.5 ± 43.54
Week 1294.3 ± 48.77
Week 2487.3 ± 43.56
Week 4888.9 ± 44.25
Week 7280.9 ± 42.67
SecondaryPercent Change From Baseline in Non-HDL-C Over Time
Time frame:
Up to week 72
Reported as:
Mean · Percent Change
Percent Change From Baseline in Non-HDL-C Over Time
Percent ChangeAlirocumab 75 Q2W/Up150 Q2W
Week 8-40.35 ± 27.470
Week 12-36.89 ± 29.567
Week 24-41.47 ± 26.763
Week 48-42.33 ± 28.728
Week 72-43.28 ± 29.534
SecondaryHigh-density Lipoprotein Cholesterol (HDL-C) Values From Baseline Over Time

The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

Time frame:
Up to week 72
Reported as:
Mean · mg/dL
High-density Lipoprotein Cholesterol (HDL-C) Values From Baseline Over Time
mg/dLAlirocumab 75 Q2W/Up150 Q2W
Baseline47.1 ± 13.92
Week 851.0 ± 14.82
Week 1250.6 ± 13.95
Week 2449.9 ± 14.80
Week 4850.5 ± 14.66
Week 7250.8 ± 14.61
SecondaryPercent Change From Baseline in HDL-C Over Time
Time frame:
Up to week 72
Reported as:
Mean · Percent Change
Percent Change From Baseline in HDL-C Over Time
Percent ChangeAlirocumab 75 Q2W/Up150 Q2W
Week 810.54 ± 22.735
Week 1210.33 ± 21.933
Week 248.53 ± 21.824
Week 489.81 ± 23.690
Week 729.24 ± 21.505
SecondaryFasting Triglycerides (TGs) Values From Baseline Over Time

The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

Time frame:
Up to week 72
Reported as:
Mean · mg/dL
Fasting Triglycerides (TGs) Values From Baseline Over Time
mg/dLAlirocumab 75 Q2W/Up150 Q2W
Baseline179.2 ± 146.51
Week 8154.8 ± 113.05
Week 12162.2 ± 182.00
Week 24169.3 ± 161.45
Week 48171.1 ± 131.35
Week 72156.9 ± 65.21
SecondaryPercent Change From Baseline in Fasting TGs Over Time
Time frame:
Up to week 72
Reported as:
Mean · Percent Change
Percent Change From Baseline in Fasting TGs Over Time
Percent ChangeAlirocumab 75 Q2W/Up150 Q2W
Week 8-4.68 ± 49.230
Week 12-4.29 ± 40.748
Week 240.42 ± 54.118
Week 481.54 ± 69.156
Week 72-5.97 ± 41.440
SecondaryApolipoprotein B (Apo B) Values From Baseline Over Time

The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

Time frame:
Up to week 72
Reported as:
Mean · mg/dL
Apolipoprotein B (Apo B) Values From Baseline Over Time
mg/dLAlirocumab 75 Q2W/Up150 Q2W
Baseline103.8 ± 27.25
Week 862.5 ± 27.63
Week 1268.0 ± 31.32
Week 2461.5 ± 26.20
Week 4863.7 ± 26.40
Week 7258.5 ± 25.82
SecondaryPercent Change From Baseline in Apo B Over Time
Time frame:
Up to week 72
Reported as:
Mean · Percent Change
Percent Change From Baseline in Apo B Over Time
Percent ChangeAlirocumab 75 Q2W/Up150 Q2W
Week 8-36.51 ± 34.460
Week 12-34.48 ± 27.905
Week 24-38.16 ± 24.867
Week 48-37.93 ± 23.767
Week 72-39.04 ± 26.383
SecondaryApolipoprotein-A1 (Apo A1) Values From Baseline Over Time

The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

Time frame:
Up to week 72
Reported as:
Mean · mg/dL
Apolipoprotein-A1 (Apo A1) Values From Baseline Over Time
mg/dLAlirocumab 75 Q2W/Up150 Q2W
Baseline145.3 ± 24.95
Week 8148.5 ± 24.73
Week 12149.4 ± 25.38
Week 24150.7 ± 26.36
Week 48152.6 ± 25.96
Week 72151.4 ± 26.03
SecondaryPercent Change From Baseline in Apo A1 Over Time
Time frame:
Up to week 72
Reported as:
Mean · Percent Change
Percent Change From Baseline in Apo A1 Over Time
Percent ChangeAlirocumab 75 Q2W/Up150 Q2W
Week 85.07 ± 13.385
Week 122.99 ± 13.638
Week 245.35 ± 14.108
Week 484.77 ± 13.836
Week 721.21 ± 13.170
SecondaryGonadal Hormone (Follicle Stimulating Hormone [FSH] and Luteinizing Hormone [LH]) Values for Female Participants From Baseline Over Time

The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

Time frame:
Up to week 72
Reported as:
Mean · International units per litre (IU/L)
Gonadal Hormone (Follicle Stimulating Hormone [FSH] and Luteinizing Hormone [LH]) Values for Female Participants From Baseline Over Time
International units per litre (IU/L)Alirocumab 75 Q2W/Up150 Q2W
FSH Baseline57.948 ± 26.7383
FSH Week 859.264 ± 24.7912
FSH Week 1254.279 ± 23.9923
FSH Week 2457.664 ± 25.9830
FSH Week 4856.529 ± 25.1408
FSH Week 7258.600 ± 24.5205
LH Baseline30.155 ± 13.1090
LH Week 833.794 ± 14.4459
LH Week 1230.779 ± 13.0946
LH Week 2431.260 ± 13.7344
LH Week 4829.585 ± 13.9792
LH Week 7229.248 ± 11.0829
SecondaryChange From Baseline in Gonadal Hormones (FSH and LH) for Female Participants Over Time
Time frame:
Up to week 72
Reported as:
Mean · IU/L
Change From Baseline in Gonadal Hormones (FSH and LH) for Female Participants Over Time
IU/LAlirocumab 75 Q2W/Up150 Q2W
FSH Week 8-0.765 ± 12.0083
FSH Week 12-0.984 ± 12.1584
FSH Week 24-0.575 ± 8.7780
FSH Week 48-0.877 ± 15.9972
FSH Week 72-1.861 ± 8.6119
LH Week 82.730 ± 8.2258
LH Week 121.882 ± 8.2884
LH Week 240.939 ± 6.3694
LH Week 480.367 ± 8.5631
LH Week 720.222 ± 6.8910
SecondaryGonadal (FSH and LH) Hormone Values for Male Participants From Baseline Over Time

The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

Time frame:
Up to week 72
Reported as:
Mean · International units per litre (IU/L)
Gonadal (FSH and LH) Hormone Values for Male Participants From Baseline Over Time
International units per litre (IU/L)Alirocumab 75 Q2W/Up150 Q2W
FSH Baseline8.006 ± 7.4451
FSH Week 87.959 ± 7.5500
FSH Week 127.766 ± 6.8204
FSH Week 248.268 ± 8.1355
FSH Week 489.597 ± 11.2138
FSH Week 7210.005 ± 13.2973
LH Baseline6.500 ± 4.2832
LH Week 87.094 ± 4.7226
LH Week 126.688 ± 4.4079
LH Week 246.931 ± 4.8597
LH Week 487.677 ± 6.5478
LH Week 728.173 ± 8.9083
SecondaryChange From Baseline in Gonadal Hormones (FSH and LH) for Male Participants Over Time
Time frame:
Up to week 72
Reported as:
Mean · IU/L
Change From Baseline in Gonadal Hormones (FSH and LH) for Male Participants Over Time
IU/LAlirocumab 75 Q2W/Up150 Q2W
FSH Week 80.285 ± 3.7264
FSH Week 12-0.598 ± 4.1076
FSH Week 240.331 ± 6.0522
FSH Week 480.960 ± 10.3803
FSH Week 722.458 ± 13.4730
LH Week 80.535 ± 2.4847
LH Week 12-0.136 ± 3.2638
LH Week 240.582 ± 4.4964
LH Week 481.015 ± 6.6344
LH Week 721.964 ± 9.3028
SecondaryGonadotropin (Estradiol) Values for Female Participants From Baseline Over Time

The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

Time frame:
Up to week 72
Reported as:
Mean · picomoles per litre (pmol/L)
Gonadotropin (Estradiol) Values for Female Participants From Baseline Over Time
picomoles per litre (pmol/L)Alirocumab 75 Q2W/Up150 Q2W
Baseline55.589 ± 80.8238
Week 858.676 ± 69.0119
Week 1259.673 ± 74.7587
Week 2464.304 ± 103.8955
Week 4864.503 ± 102.1595
Week 7257.926 ± 67.1795
SecondaryChange From Baseline in Gonadotropins (Estradiol) for Female Participants Over Time
Time frame:
Up to week 72
Reported as:
Mean · pmol/L
Change From Baseline in Gonadotropins (Estradiol) for Female Participants Over Time
pmol/LAlirocumab 75 Q2W/Up150 Q2W
Week 84.272 ± 77.1561
Week 129.262 ± 73.1050
Week 247.869 ± 78.4151
Week 4811.763 ± 97.5350
Week 729.569 ± 38.0952
SecondaryGonadotropin (Testosterone) Values for Male Participants From Baseline Over Time

The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

Time frame:
Up to week 72
Reported as:
Mean · nanomoles per litre (nmol/L)
Gonadotropin (Testosterone) Values for Male Participants From Baseline Over Time
nanomoles per litre (nmol/L)Alirocumab 75 Q2W/Up150 Q2W
Baseline13.4370 ± 6.36321
Week 814.5802 ± 5.99821
Week 1214.2443 ± 6.77070
Week 2413.5818 ± 6.11269
Week 4813.4798 ± 7.04977
Week 7212.7538 ± 6.37408
SecondaryChange From Baseline in Gonadotropins (Testosterone) for Male Participants Over Time
Time frame:
Up to week 72
Reported as:
Mean · nmol/L
Change From Baseline in Gonadotropins (Testosterone) for Male Participants Over Time
nmol/LAlirocumab 75 Q2W/Up150 Q2W
Week 80.6030 ± 4.46401
Week 120.7965 ± 4.74765
Week 240.1946 ± 5.89220
Week 480.0498 ± 6.34201
Week 721.2569 ± 5.29335
SecondaryAlanine Aminotransferase Values From Baseline Over Time

The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

Time frame:
Up to week 72
Reported as:
Mean · U/L (Units per Liter)
Alanine Aminotransferase Values From Baseline Over Time
U/L (Units per Liter)Alirocumab 75 Q2W/Up150 Q2W
Baseline0.516 ± 0.3218
Week 80.468 ± 0.2745
Week 120.505 ± 0.4940
Week 240.493 ± 0.2851
Week 480.533 ± 0.3267
Week 720.468 ± 0.2340
SecondaryChange From Baseline in Alanine Aminotransferase Over Time
Time frame:
Up to week 72
Reported as:
Mean · U/L
Change From Baseline in Alanine Aminotransferase Over Time
U/LAlirocumab 75 Q2W/Up150 Q2W
Week 8-0.025 ± 0.3006
Week 120.009 ± 0.5189
Week 24-0.036 ± 0.3294
Week 48-0.027 ± 0.3052
Week 72-0.062 ± 0.1872
SecondaryAspartate Aminotransferase Values From Baseline Over Time

The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

Time frame:
Up to week 72
Reported as:
Mean · U/L
Aspartate Aminotransferase Values From Baseline Over Time
U/LAlirocumab 75 Q2W/Up150 Q2W
Baseline0.553 ± 0.2516
Week 80.520 ± 0.2536
Week 120.527 ± 0.2698
Week 240.544 ± 0.3071
Week 480.565 ± 0.2773
Week 720.556 ± 0.2256
SecondaryChange From Baseline in Aspartate Aminotransferase Over Time
Time frame:
Up to week 72
Reported as:
Mean · U/L
Change From Baseline in Aspartate Aminotransferase Over Time
U/LAlirocumab 75 Q2W/Up150 Q2W
Week 8-0.022 ± 0.2856
Week 12-0.017 ± 0.3004
Week 24-0.013 ± 0.2901
Week 48-0.019 ± 0.2390
Week 72-0.037 ± 0.1730
SecondaryAlkaline Phosphatase Values From Baseline Over Time

The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

Time frame:
Up to week 72
Reported as:
Mean · U/L
Alkaline Phosphatase Values From Baseline Over Time
U/LAlirocumab 75 Q2W/Up150 Q2W
Baseline0.601 ± 0.1865
Week 80.635 ± 0.2151
Week 120.605 ± 0.1865
Week 240.602 ± 0.2012
Week 480.602 ± 0.2657
Week 720.553 ± 0.1678
SecondaryChange From Baseline in Alkaline Phosphatase Over Time
Time frame:
Up to week 72
Reported as:
Mean · U/L
Change From Baseline in Alkaline Phosphatase Over Time
U/LAlirocumab 75 Q2W/Up150 Q2W
Week 80.009 ± 0.1371
Week 120.013 ± 0.1203
Week 240.006 ± 0.1152
Week 480.024 ± 0.2333
Week 72-0.011 ± 0.1029
SecondaryTotal Bilirubin Values From Baseline Over Time

The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)

Time frame:
Up to week 72
Reported as:
Mean · micromoles per litre (umol/L)
Total Bilirubin Values From Baseline Over Time
micromoles per litre (umol/L)Alirocumab 75 Q2W/Up150 Q2W
Baseline10.76 ± 4.736
Week 810.01 ± 4.123
Week 1210.26 ± 4.758
Week 2410.41 ± 4.922
Week 4810.06 ± 4.503
Week 728.82 ± 3.770
SecondaryChange From Baseline in Total Bilirubin Over Time
Time frame:
Up to week 72
Reported as:
Mean · umol/L
Change From Baseline in Total Bilirubin Over Time
umol/LAlirocumab 75 Q2W/Up150 Q2W
Week 8-0.37 ± 3.120
Week 12-0.44 ± 3.854
Week 24-0.48 ± 3.962
Week 48-0.05 ± 3.991
Week 720.71 ± 2.152

Adverse events

Collected over Adverse events were recorded from the time of signed informed consent until the end of study, up to 80 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alirocumab 75 Q2W/Up150 Q2W5/1,385 (0.4%)89/1,385 (6.4%)0/1,385 (0%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventAlirocumab 75 Q2W/Up150 Q2W
Angina unstableCardiac disorders10/1385
Angina pectorisCardiac disorders8/1385
Atrial fibrillationCardiac disorders6/1385
Acute myocardial infarctionCardiac disorders5/1385
PneumoniaInfections and infestations4/1385
Chest painGeneral disorders3/1385
Acute left ventricular failureCardiac disorders2/1385
Cardiac failure congestiveCardiac disorders2/1385
Coronary artery diseaseCardiac disorders2/1385
Cerebrovascular accidentNervous system disorders2/1385

Baseline characteristics

Demographic and other baseline characteristics were based on the data collected in R727-CL-1532 (NCT02957682). The baseline value was generally defined as the last available value before the first dose of double-blind study treatment in that study.

Age, Continuous
Age, Continuous(Years)Alirocumab 75 Q2W/Up150 Q2W
Mean64.6 ± 8.63
Sex: Female, Male
Sex: Female, Male(Participants)Alirocumab 75 Q2W/Up150 Q2W
Female527
Male858
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Alirocumab 75 Q2W/Up150 Q2W
Hispanic or Latino10
Not Hispanic or Latino1372
Unknown or Not Reported3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Alirocumab 75 Q2W/Up150 Q2W
White1178
Black or African American81
Asian7
American Indian or Alaska Native1
Native Hawaiian or Other Pacific Islander0
Other118
08

Study locations

124 sites
  • Regeneron Research Site
    Auburn, Alabama 36830, United States
  • Regeneron Research Site
    Mobile, Alabama 36608, United States
  • Regeneron Research Site
    Beverly Hills, California 90210, United States
  • Regeneron Research Site
    Los Gatos, California 95032, United States
  • Regeneron Research Site
    North Hollywood, California 91606, United States
  • Regeneron Research Site
    Port Hueneme, California 93041, United States
  • Regeneron Research Site
    Aurora, Colorado 80012, United States
  • Regeneron Research Site
    Colorado Springs, Colorado 80906, United States
  • Regeneron Research Site
    Lake Worth, Florida 33461, United States
  • Regeneron Research Site
    Miami Springs, Florida 33166, United States
  • Regeneron Research Site
    Champaign, Illinois 61822, United States
  • Regeneron Research Site
    Evansville, Indiana 47714, United States
  • Regeneron Research Site
    Indianapolis, Indiana 46237, United States
  • Regeneron Research Site
    Ames, Iowa 50010-30144, United States
  • Regeneron Research Site
    Iowa City, Iowa 52242, United States
  • Regeneron Research Site
    Waterloo, Iowa 50702, United States
  • Regeneron Research Site
    Newton, Kansas 67114, United States
  • Regeneron Research Site
    Louisville, Kentucky 40213, United States
  • Regeneron Research Site
    Bangor, Maine 04401, United States
  • Regeneron Research Site
    Baltimore, Maryland 21229, United States
  • Regeneron Research Site
    Oxon Hill, Maryland 20745, United States
  • Regeneron Research Site
    Olive Branch, Mississippi 38654, United States
  • Regeneron Research Site
    Washington, Missouri 63090, United States
  • Regeneron Research Site
    Buffalo, New York 14215, United States
  • Regeneron Research Site
    New Hyde Park, New York 11042, United States
  • Regeneron Research Site
    Cary, North Carolina 27518, United States
  • Regeneron Research Site
    Charlotte, North Carolina 28209, United States
  • Regeneron Research Site
    Charlotte, North Carolina 28277, United States
  • Regeneron Research Site
    Greensboro, North Carolina 27401, United States
  • Regeneron Research Site
    Hickory, North Carolina 28601, United States
  • Regeneron Research Site
    Raleigh, North Carolina 27609, United States
  • Regeneron Research Site
    Rocky Mount, North Carolina 27804, United States
  • Regeneron Research Site
    Salisbury, North Carolina 28144, United States
  • Regeneron Research Site
    Statesville, North Carolina 28625, United States
  • Regeneron Research Site
    Wilmington, North Carolina 28401, United States
  • Regeneron Research Site
    Winston-Salem, North Carolina 27103, United States
  • Regeneron Research Site
    Cincinnati, Ohio 45219, United States
  • Regeneron Research Site
    Cleveland, Ohio 44122, United States
  • Regeneron Research Site
    Dayton, Ohio 45414, United States
  • Regeneron Research Site
    Charleston, South Carolina 29407, United States
  • Regeneron Research Site
    Summerville, South Carolina 29485, United States
  • Regeneron Research Site
    Rapid City, South Dakota 57701, United States
  • Regeneron Research Site
    Bristol, Tennessee 37620, United States
  • Regeneron Research Site 2
    Knoxville, Tennessee 37760, United States
  • Regeneron Research Site 3
    Knoxville, Tennessee 37912, United States
  • Regeneron Research Site
    Knoxville, Tennessee 37938, United States
  • Regeneron Research Site
    Powell, Tennessee 37849, United States
  • Regeneron Research Site
    Dallas, Texas 75231, United States
  • Regeneron Research Site
    Houston, Texas 77027, United States
  • Regeneron Research Site
    Schertz, Texas 78154, United States
  • Regeneron Research Site
    Shavano Park, Texas 78213, United States
  • Regeneron Research Site
    Shavano Park, Texas 78231, United States
  • Regeneron Research Site
    Falls Church, Virginia 22042, United States
  • Regeneron Research Site
    Winchester, Virginia 22601, United States
  • Regeneron Research Site
    Tacoma, Washington 98405, United States
  • Regeneron Research Site
    Walla Walla, Washington 99362, United States
  • Regeneron Research Site
    Manitowoc, Wisconsin 54220, United States
  • Regeneron Research Site
    Pleven, 5800, Bulgaria
  • Regeneron Research Site
    Plovdiv, 4000, Bulgaria
  • Regeneron Research Site
    Sofia, 1309, Bulgaria
  • Regeneron Research Site
    Sofia, 1407, Bulgaria
  • Regeneron Research Site #2
    Sofia, 1784, Bulgaria
  • Regeneron Research Site
    Stara Zagora, 6000, Bulgaria
  • Regeneron Research Site
    Varna, 9000, Bulgaria
  • Regeneron Research Site
    Tallinn, Harjumaa 10138, Estonia
  • Regeneron Research Site
    Paide, 72713, Estonia
  • Regeneron Research Site #2
    Tallinn, 10128, Estonia
  • Regeneron Research Site
    Tallinn, 10617, Estonia
  • Regeneron Research Site
    Tartu, 51014, Estonia
  • Regeneron Research Site
    Ekaterinburg, 620109, Russian Federation
  • Regeneron Research Site
    Ivanovo, 153012, Russian Federation
  • Regeneron Research Site
    Kirov, 610014, Russian Federation
  • Regeneron Research Site
    Moscow, 121309, Russian Federation
  • Regeneron Research Site
    Moscow, 121359, Russian Federation
  • Regeneron Research Site
    Moscow, 121552, Russian Federation
  • Regeneron Research Site
    Novosibirsk, 630008, Russian Federation
  • Regeneron Research Site
    Rostov-na-Donu, 344068, Russian Federation
  • Regeneron Research Site
    Saint Petersburg, 197376, Russian Federation
  • Regeneron Research Site
    Saint-Petersburg, 193312, Russian Federation
  • Regeneron Research Site
    Saint-Petersburg, 198205, Russian Federation
  • Regeneron Research Site
    Saratov, 410028, Russian Federation
  • Regeneron Research Site #2
    St. Petersburg, 192288, Russian Federation
  • Regeneron Research Site
    St. Petersburg, 192288, Russian Federation
  • Regeneron Research Site
    St. Petersburg, 195112, Russian Federation
  • Regeneron Research Site
    St. Petersburg, 197376, Russian Federation
  • Regeneron Research Site
    St. Petersburg, 197706, Russian Federation
  • Regeneron Research Site
    Sverdlovskaya, 620109, Russian Federation
  • Regeneron Research Site
    Tyumen, 625032, Russian Federation
  • Regeneron Research Site 1
    Yaroslavl, 150030, Russian Federation
  • Regeneron Research Site 2
    Yaroslavl, 150030, Russian Federation
  • Regeneron Research Site
    Kuilsrivier, Cape Town 7580, South Africa
  • Regeneron Research Site
    Parow, Cape Town 7500, South Africa
  • Regeneron Research Site
    Port Elizabeth, Eastern Cape 6001, South Africa
  • Regeneron Research Site
    Halfway House, Gauteng 1685, South Africa
  • Regeneron Research Site
    Pretoria West, Gauteng 183, South Africa
  • Regeneron Research Site
    Pretoria, Gauteng 0002, South Africa
  • Regeneron Research Site
    Pretoria, Gauteng 0122, South Africa
  • Regeneron Research Site
    Pretoria, Gauteng 0184, South Africa
  • Regeneron Research Site
    Kempton Park, Johannesburg 1619, South Africa
  • Regeneron Research Site
    Soweto, Johannesburg 1818, South Africa

Showing the first 100 of 124 sites across 6 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Apr 2020, 18 months.

Results were first posted in Jun 2021, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2018
First posted
Oct 3, 2018
StartActual
Sep 28, 2018
Primary completionActual
Apr 8, 2020
CompletionActual
Apr 8, 2020
Results first posted
Jun 15, 2021
Last update
Jun 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03694197
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Oct 3, 2018
Start date
Sep 28, 2018
Primary completion
Apr 8, 2020
Completion
Apr 8, 2020
Results posted
Jun 15, 2021
Last update
Jun 15, 2021

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion